MAL Stats & Data
NCCc1cc(OC)c(OCC(C)=C)c(OC)c1FOXJFBFFGULACD-UHFFFAOYSA-NReceptor Profile
Receptor Actions
Toxicity
PsychonautWikiThe toxicity and long-term health effects of recreational methallylescaline use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because methallylescaline is a research chemical with very little history of human usage. Anecdotal evidence suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this substance.
Effect Profile
Curated + 12 ReportsStrong visuals, headspace, and auditory effects with moderate body load
Community Effects
TripSitTolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Acute tolerance: develops within a single session — the reset numbers above apply after sustained heavy use, not after one binge. Within-session tachyphylaxis usually resets largely overnight.
Rapid tolerance develops to classical psychedelics and cross‑tolerance is well‑documented between LSD and mescaline; MAL is inferred to follow a similar 5‑HT2A‑mediated pattern. Values above are heuristic for planning intervals, not pharmacokinetic half‑life. Data quality primarily anecdotal with inference from classic literature.
Cross-Tolerances
Experience Report Analysis
ErowidDemographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 12 experience reports (12 single-substance Erowid)
Effect Sentiment Distribution
Confidence Distribution
Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.
Too few reports for bars: these effects come from 12 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?
Positive Effects 9
Adverse Effects 7
Dosage Distribution
Dose distribution from experience reports, one dose per report (the first listed). Values above Q3 + 3×IQR are left out as outliers.
Real-World Dose Distribution
62K DosesFrom 25 individual dose entries. Values above Q3 + 3×IQR are left out as outliers.
Oral (n=23)
Common Combinations
Most co-occurring substances, as a share of all 21 reports filed under MAL; whiskers are 95% intervals
Form / Preparation
Most common forms and preparations, as a share of the 12 reports that give one
Too few reports for bars: these forms come from 12 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?
- Powder / Crystals 6 of 12
- Liquid 3 of 12
- Capsule 3 of 12
Body-Weight Dosing
Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Values above Q3 + 3×IQR are left out as outliers.
Redose Patterns
Redosing behavior across 13 reports
Too few reports for a chart: redosing is known from 13 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?
- Single dose 11 of 13
- Redosed 2 of 13
Harm Reduction
drugs.wiki- Identity and nomenclature: MAL is 3,5-dimethoxy-4-methallyloxyphenethylamine; the methallyl (2‑methylallyl) ether at the 4-position makes it an escaline-family analogue. This specific naming helps distinguish it from mescaline analogues with 3,4,5-trimethoxy patterns. (Source: PiHKAL·info entry and IUPAC listing).
- Very slow, sometimes deceptive onset (60–120 min) is frequently reported; premature redosing is a common cause of excessive body-load and adverse effects—avoid any redose before 3 hours and consider split-dosing only after prior experience. (Anecdotal consensus across BL/Erowid).
- Long duration (10–16 h) plus residual after-effects can impact sleep and next-day function; don’t drive, cycle, swim, or operate machinery during and after. Plan an unhurried, temperature‑controlled setting with trusted support.
- Nausea and GI cramping are common in the first hours; bland pre-meal, ginger/peppermint, and avoiding heavy fats can help. Some find sublingual/insufflation reduces nausea but increases stimulation and local irritation. (Anecdotal).
- Peripheral stimulation/vasoconstriction and mild hypertension can occur; combining with stimulants (including high-dose caffeine) increases cardiovascular strain—avoid such mixes, especially if you have cardiovascular risk factors. (General HR + TripSit chart rationale).
- Urinary retention has been repeatedly reported anecdotally with moderate–high doses; inability to void for many hours is a red flag. Avoid anticholinergics (e.g., diphenhydramine), stay hydrated with electrolytes, and seek urgent care if painful retention persists (>6–8 h), if there’s flank pain, or if you feel systemically unwell. Do not self‑medicate with prescription alpha‑blockers without medical supervision. (Anecdotal; community warnings).
- Salt forms: “MAL fumarate” has appeared in drug checking contexts and can be laid on blotter. Salt form changes mg‑for‑mg potency by mass; if unknown, titrate from the low end and do an allergy test with each new batch.
- Reagent/drug checking: MAL has been found on blotter, a format often used for long‑acting phenethylamines; always test. Reagents may not be definitive; GC/MS (e.g., DrugsData) or a local service provides confirmation.
- Allergy test: For any new batch, especially RCs, start with 1–2 mg to screen idiosyncratic reactions, then stepwise titrate on a different day.
- Mental set: As with other psychedelics, strong alterations in thought and perception occur; having a sober sitter, a plan for anxiety management (breathing, environment control), and avoiding emotionally charged settings reduces risk.
- Medical cautions: People with BPH/prostate issues, urinary tract problems, uncontrolled hypertension, or significant cardiovascular disease should avoid MAL without medical clearance due to retention and BP risks.
- Do not mix with lithium (seizure/coma risk reported with psychedelics) or MAOIs (unpredictable potentiation and hypertension risk). Tramadol is risky due to serotonergic and seizure‑threshold effects.
- Hydration: Sip fluids regularly; add electrolytes if sweating or active. Overhydration can be harmful—avoid chugging large volumes rapidly.
- Sleep protection: Expect sleep disruption; prepare a dark, quiet space and non-pharmacologic sleep hygiene rather than sedative stacking post‑trip.
References
Cited References
- Bluelight: The Big & Dandy Methallylescaline Thread
- Erowid Experience Vault: Methallylescaline
- PIHKAL Entry #99: Methallylescaline
- PsychonautWiki: Methallylescaline
- Smolecule: Methallylescaline Chemical Profile
- TripSit Wiki: Drug Combinations Chart
- Wikipedia: Methallylescaline
- Bluelight: Big & Dandy Methallylescaline Thread
- TripSit Factsheet: Methallylescaline
- PiHKAL Mirror: Pihkal
Additional references
- Isomer Design entry for Methallylescaline (names/IUPAC; links; MAL fumarate noted)
- Erowid Methallylescaline Experience Vault (dose/duration user ranges; slow onset)
- Bluelight Big & Dandy Methallylescaline Thread (dose ranges, slow come up, nausea/body load)
- Bluelight MAL dosing discussion (typical 40–60 mg oral; redose cautions)
- Reddit: MAL urinary retention/kidney function warning ( community anecdotal)
- Reddit: Managing MAL urinary retention (anecdotal tamsulosin post; not advice)
- Reddit MAL ROA anecdotes – insufflated 50 mg strong; sublingual 5–10 mg mild
- TripSit drug combinations chart (general HR rationale re: psychedelics + stimulants)
- Bluelight: Main LSD & Lithium thread (seizure/coma risk reports)
- Erowid Extracts / classic text: cross‑tolerance between LSD and mescaline
- Erowid DrugsData project overview (GC/MS checking resource)
- PubChem entry (synonyms/identifier)